Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Regadenoson Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 14/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regadenoson Anhydrous SCHEMBL19387116 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL20128455 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL14131217 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL12958830 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL8925057 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL13462149 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL15472806 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL6745611 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL21710782 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL2558796 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47351-E1 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180127452-A1 | NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF | APICORE US LLC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9624258-B2 | Polymorph of regadenoson | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-04-18 | — | — | US | disclosed |
| US-9624258-B2 | Polymorph of regadenoson | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-04-18 | — | — | US | disclosed |
| US-9580457-B2 | Process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9580457-B2 | Process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-02-28 | — | — | US | disclosed |
| US-20160115191-A1 | Novel Polymorph of Regadenoson | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2016-04-28 | — | — | US | disclosed |
| US-20160115191-A1 | Novel Polymorph of Regadenoson | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2016-04-28 | — | — | US | disclosed |
| US-9289446-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289446-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008086096-A2 | MYOCARDIAL PERFUSION IMAGING | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7183264-B2 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20160115191-A1 | Novel Polymorph of Regadenoson | UGT1A6, PARP16, POLR1A | ADORA2A 2345/4885ADORA3 1325/4885ADORA1 1831/4885 |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20180127452-A1 | NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF | PRPF6, CYP2D6, ADH1A | ADORA2A 873/4885ADORA3 674/4885ADORA1 1058/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | ADORA2A 1/4885ADORA3 2/4885ADORA1 8/4885 |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.